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Tumour enhancing fraction (EnF) in glioma:
relationship to tumour grade
Abstract The aim of this research
was to determine whether the propor-
tion of a tumour that enhances (en-
hancing fraction, EnF) and changes in
EnF with enhancement threshold dif-
fer between low and high grade glio-
ma. Forty-four patients (45 gliomas
comprising 16 grade II, 5 grade III and
24 grade IV) were studied. Imaging
included pre- and post-contrast-en-
hanced T1-weighted sequences and
T1-weighted DCE-MRI. Thresholded
enhancement maps were generated for
each tumour by using a range of
values of the initial area under the
contrast concentration curve (IAUC).
A plot of EnF versus threshold value
was generated. We examined the
relationship between tumour grade
and enhancement metrics including:
EnF (threshold IAUC>0 mMol s),
EnF (threshold IAUC>2.5 mMol s),
initial slope of the EnF/threshold
curve (∂EnF), IAUC, and two pre-
viously described signal-intensity-
based metrics. EnF, defined as the
proportion of tumour showing any
enhancement (threshold IAUC>
0 mMol s), showed no difference
between low and high grade glioma.
All other measures demonstrated sig-
nificant differences between grade II
and IV, and low (grade II) and high
grade (grades III/ IV) gliomas (p<
0.01). Two measures, ∂EnF and Pro-
nin’s measure of enhancement,
showed differences between grade III
and IV (p<0.05). No measure sepa-
rated grade II from III. Metrics which
describe the enhancing fraction and its
variation with enhancement threshold
∂EnF show considerably different
behaviour in low and high grade
tumours. These observations suggest
that these metrics may provide
important biological information
concerning tumour biology and
therapeutic responses and encourage
further research to characterise and
validate these novel biomarkers.
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Introduction
Glioblastoma multiforme (GBM) is one of the commonest,
aggressive and vascular primary brain tumours in adults.
The tumours are structurally heterogenous, characterised by
varying degrees of hypercellularity, cytoplasmic and nuclear
pleopmorphism, mitoses and endothelial proliferation.
Microvascular proliferation is a prominent feature and
most marked in areas of necrosis and at the tumour–brain
interface [1]. The marked spatial heterogeneity of histological
features is accompanied by regional variations in vascular
development and maturity, vascular density, blood flow,
oxygenation, pH, and interstitial pressure. Some effects of
this heterogeneity are well known; for example, areas of
hypoperfusion and hypoxia are associated with poor
chemotherapy delivery and poor radiotherapy response [2].
The proportion of a tumour which is perfused, expressed
as the enhancing fraction (EnF), has been proposed as a
simple measure of bulk tumour perfusion [3, 4]. EnF has
been shown to predict outcome to first-line chemotherapy in
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patients with advanced ovarian cancer [5] and to change
rapidly in response to drug-induced variations in tumour
interstitial pressure [3]. EnF is a potentially interesting
metric since it differs from conventional measurements of
microvascular structure and function in a number of
potentially important ways. Firstly, conventional microvas-
cular parameters such as regional blood volume (CBV) are
highly heterogeneous in glial tumours and mean or median
values are by definition unrepresentative [6].Many research
studies select the region of the tumour in which to make
these measurements so that, for instance, the well-
established relationship between CBV and tumour grade
is based on some reports which have deliberately selected
the highest areas of CBV [7] and others which report
average values from all enhancing tumour tissue [8, 9]. In
comparison, EnF describes the perfusion characteristics of
the tumour as a whole and will be significantly affected by
regional variations in perfusion pressure and by global
intracranial pressure. Secondly, EnF is a model-free
parameter which, if clinically useful, will be easy to
implement in a clinical environment, thus offering a simple
alternative to parametric modelling approaches.
Measurement of EnF requires the classification of all
tumour pixels as enhancing or nonenhancing. Conven-
tional imaging relies upon the radiologist’s subjective
ability to identify enhancement following intravenous
administration of contrast agents. Subjective contrast
enhancement is seen in almost all high grade and some
low grade glioma [10, 11]. Subtle changes, due to minimal
enhancement, are open to errors of interpretation and a
number of groups have described quantitative approaches.
These include measurement of tumour signal intensity
relative to contralateral normal-appearing white matter on
either enhanced T1-weighted images [12, 13] or on T1-
weighted images before and after intravenous administra-
tion of gadolinium [14, 15]. Regional changes in these
measurements have shown promise in early prediction of
malignant transformation of low grade tumours [15] and
correlate with the amount of surrounding oedema in high
grade tumours [13]. An alternative approach to quantify the
intensity of enhancement is to measure the concentration of
contrast agent within tissue. This can be done on single
enhanced images but dynamic contrast-enhanced MRI
(DCE-MRI) provides additional data describing regional
changes in contrast occupancy over time. The initial area
under the concentration curve (IAUC) is a simple model-
free metric which has been widely used to quantify contrast
enhancement in tumours on both DCE-MRI and dynamic
CT [16, 17].
EnF can therefore be calculated by measuring the
proportion of voxels within a tumour with a measurable
IAUC (>0 mMol s). This simple measure identifies the
presence of enhancement but does not attempt to quantify
the intensity. Applying different threshold values of IAUC,
above which a voxel is considered to be enhancing, will
characterize the relationship between EnF and the
intratumoural variations in the local concentration of
contrast agent.
The aim of this research is to determine whether the EnF
parameter provides any significant biological information
over and above that provided by conventional microvas-
cular biomarkers. The specific objective of this report is to
provide an initial description of the behaviour of the EnF
parameter in glial cell tumours where it will be affected by
a wide range of physiological features such as the presence
of the blood–brain barrier and variations in intracranial
pressure that are not relevant in systemic tumours. We have
therefore examined the relationship between EnF and
tumour grade, described the effect of changing IAUC
thresholds on EnF and compared EnF to other previously
described measures for quantifying enhancement based
upon signal intensity.
Materials and methods
A prospective study was performed following institutional
and ethics committee review.
Patients
Patients were identified via the neuro-oncology multi-
disciplinary team or neurosurgical radiology meetings at
Salford Royal Hospitals NHS Trust. All imaging was
performed before surgery. All tumours were histologically
confirmed as gliomas and were graded according to the
WHO classification criteria [18]. All patients with grade IV
tumours received corticosteroids treatment for a minimum
of 48 h prior to imaging. No patients were receiving any
other form of treatment at the time of imaging. All patients
provided written informed consent in accordance with local
research and ethics committee approval.
Data acquisition
Imaging was performed using a SENSE head coil on a 3-T
Philips Achieva system (Philips Medial Systems, Best, NL)
at the Translational Imaging Unit, based at Salford Royal
Hospitals NHS Trust. Conventional anatomical sequences
were chosen according to those used in routine clinical
practice and included:
1. axial T1 inversion recovery (TR 8.4 ms, TE 3.8 ms,
inversion time 1,150 ms, slice thickness 1.8 mm, 256×
256),
2. axial T2 (TR 3,000 ms, TE 80 ms, slice thickness
3.0 mm, 1,024×1,024),
3. coronal T2 FLAIR (TR 11,000 ms, TE 120 ms,
inversion time 2,800 ms, slice thickness 3.0 mm, 512×
512), and
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4. T1 3D volume acquisition (TR 9.8 ms, TE 4.6 ms, slice
thickness 1 mm, 256×256) following intravenous
administration of contrast medium.
Four unenhanced spoiled fast field echo (T1-FFE spoiled
gradient echo) sequences with different flip angles (2°, 5°,
10°, 16°) were acquired in the same geometry for
calculation of baseline T1 maps (TR 3.5 ms, TE 1.1 ms,
slice thickness 4.2 mm, 128×128) using the standard
variable flip angle relationship [19] in order to allow
calculation of baseline relaxivity and thereby calculate
changes in contrast concentration during the subsequent
dynamic contrast-enhanced image acquisition. This was
followed by a dynamic contrast-enhanced acquisition
series with identical acquisition parameters as the variable
flip angle baseline T1 measurement and a 15° flip angle.
The series consisted of 100 volumes with temporal spacing
of approximately 3.4 s. Gadolinium-based contrast agent
(Gd-DTPA-BMA; Omniscan, GE Healthcare, Amersham,
UK) was injected as a bolus of dose of 0.1 mmol kg−1 of
body weight, at 3 ml s−1, after acquisition of the fifth image
volume.
Data analysis
Assessment of visible enhancement on conventional
imaging and tumour volumes of interest (VOIs) were
defined for each tumour by an experienced neuroradiolo-
gist (SJM), before histological diagnosis was confirmed.
Post processing analysis was performed using in-house
software (MaDyM, Manchester Dynamic Modelling).
Baseline T1 images were calculated from the variable flip
angle acquisitions and these values were used to calculate
contrast concentration values for images in the dynamic
image acquisition. Contrast concentration time course
images were then used to generate parametric maps of
IAUC60 (the IAUC calculated over a 60-s period following
the bolus of contrast) were produced.
EnF was calculated by dividing the volume of enhancing
tissue (IAUC60>0 mMol s) by the total tumour volume.
Thresholded EnF curves were plotted for each tumour by
calculating EnF at different thresholds of IAUC60. An
initial analysis was performed on a subset of five grade II
and ten grade IV gliomas to identify an appropriate
IAUC60 threshold that provided the greatest discrimina-
tion between histological grade in this subgroup. This was
done to allow division of the data into bins for statistical
analysis. Mean curves were generated for the grade II and
grade IV gliomas and the maximum difference between the
two curves indicated the optimum threshold of IAUC60
(2.5 mMol s) for distinguishing between grades (Fig. 1).
The following metrics were calculated for each tumour:
EnF where IAUC60>0 mMol s (EnFIAUC60>0), enhancing
fraction where IAUC60>2.5 mMol s (EnFIAUC60>2.5), the
initial gradient of the EnF/IAUC curve, ∂EnF (between
IAUC60=0 and 2.5 mMol s) which represents the rate at
which pixels are eliminated from the enhancing component
Fig. 1 Mean calculated enhan-
cing fraction for different
IAUC60 thresholds. Initial da-
taset of five grade II gliomas
(triangles) and ten grade IV
gliomas (circles). The error bars
represent the standard error. The
point of maximum difference
between tumour grades was
identified by subtracting the
mean low grade curve from the
mean high grade curve to plot a
curve of difference (dashed
curve). The optimised IAUC60
threshold (dashed line) was
identified from this curve
(=2.5 mMol s). The ∂EnF
(dotted line) was defined as the
initial average gradient of a
thresholded enhancement curve
between IAUC60 thresholds of
0 mMol s and 2.5 mMol s
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of the tumour as the threshold value of IAUC increases
(Fig. 1). In addition measures of enhancement based on
signal intensity were performed using methods adapted
from previously described techniques by Pronin and Tofts
(Appendix). Tofts’ measure of enhancement, %E, gener-
ates values for each voxel, the median value of %E for the
whole tumour was therefore calculated to allow statistical
comparison with the other measures of enhancement.
Statistical analysis
Statistical analysis was performed using SPSS (version
15.0, SPSS Inc., Chicago, USA) and MedCalc (MedCalc
Software) was used for pairwise comparison of receiver
operator characteristic (ROC) curves. Differences between
the measured variables (EnFIAUC60>0, EnFIAUC60>2.5,
∂EnF, median IAUC60, Pronin’s degree of enhancement
and median %E) for individual tumour grades were tested
using analysis of variance (ANOVA) with a posteriori
pairwise testing using Tamhanes analysis (unequal var-
iances assumed). A discriminant analysis was performed to
assess the potential value of the variables in predicting
histological grade, and ROC curves were generated for
each variable for predicting grade II versus grade III, grade
II versus grade IV, grade III versus grade IV, and low grade
(II) versus high grade (III and IV) tumours.
Results
Forty-four patients (18 female; 26 male) with a mean age of
48 years (range 18–77 years, standard deviation=16 years)
were recruited for this study. There were 16 grade II (6
astrocytomas, 3 oligoastrocytomas and 7 oligodendroglio-
mas), 5 grade III (4 anaplastic astrocytomas and 1
anaplastic oligodendroglioma), and 24 grade IV gliomas
(23 glioblastoma multiforme and 1 gliosarcoma); one
patient had bilateral grade II tumours each of distinct
histological subtype (astrocytoma and oligodendroglioma).
Fig. 2 Clustered boxplots of
various enhancement measures





sures of enhancement; Pronin’s
degree of enhancement and
Tofts’ %E and c median
IAUC60
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Five grade II tumours (1 astrocytoma, 1 oligoastrocytoma
and 3 oligodendrogliomas), one grade III and all grade IV
tumours demonstrated radiologically visible contrast en-
hancement on conventional imaging.
EnFIAUC60>0 did not distinguish between individual
histological grade (p=0.894) or between low and high
grade tumours (p=0.822) (Fig. 2). Curves of EnF versus
IAUC demonstrated clear differences between grade II and
IV, grade III and IV, and low and high grade tumours, but
not between grade II and III (Fig. 3). ∂EnF was significantly
different between grade II and IV (p<0.0005), aswasmedian
IAUC60 (p<0.0005), EnFIAUC60>2.5 (p<0.0005) and both
signal-intensity-based measures of enhancement (Pronin’s
p<0.0005 and Tofts’ %E p=0.001). Similarly, these mea-
sures also distinguished between low and high grade
tumours (RoPE p<0.0005, median IAUC60 p<0.0005,
EnFIAUC60>2.5 p<0.0005, Pronin’s p<0.0005 and Tofts’ %E
p=0.004) and between grade III and IV tumours (RoPE
p<0.0005, median IAUC60 p<0.0005, EnFIAUC60>2.5
p<0.0005, Pronin’s p<0.0005 and Tofts’ %E p=0.007)
(Fig. 2). No single measure distinguished grade II from grade
III gliomas.
A stepwise discriminant analysis identified two canoni-
cal variables, ∂EnF (Wilks’ lambda=0.267, F=57.543,
p<0.0005) and Pronin’s measure of enhancement (Wilks’
lambda=0.211, F=24.143, p<0.0005) as independent
discriminants of histological grade, with RoPE accounting
for 100% of the variance. The discriminant correctly
classified 82.2% of all tumours, 93.8% of grade II tumours
and 91.7% of grade IV tumours, but was unable to correctly
classify any grade III tumour. ROC curves of all variables
in predicting grade II from III, II from IV, III from IV and
IV with the area under curve (AUC) measures are shown in
Fig. 4. Table 1 denotes the pairwise comparisons of ROC
curves for all variables in each analysis. In the analysis of
grade II versus grade IV the ROC curve for EnFIAUC60>0
was significantly different, with a lower AUC, than all
other variables (p<0.001) and the curve for Tofts’ %E was
significantly different from ∂EnF (p=0.024). Comparison
of low versus high grade showed only the variable
EnFIAUC60>0 to differ significantly from all other variables.
There were insufficient numbers for formal statistical
analysis of patients based on histological subtype of grade
II and III tumours, although a tendency was seen for
increasing EnFIAUC60>0 in tumours with an oligodendro-
glial component (Fig. 5).
Discussion
This study was designed to examine the behaviour of EnF
in cerebral tumours. The EnF has been proposed as a
simple measure of bulk tumour perfusion [3, 4]. EnF has
been shown to predict outcome to first-line chemotherapy
Fig. 3 Mean thresholded en-
hancement curves for all grades
of tumour. Clear differences
were seen between grade II and
IV tumours, but not grade II and
III. Grade II glioma (triangles,
n=16), grade III glioma (crosses,
n=5) and grade IV glioma
(circles, n=24). Error bars were
of a similar magnitude to those in
Fig. 1 but have been excluded for
improved visualisation of the
separate grade II and III curves
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in patients with advanced ovarian cancer [5] where
nonenhancement principally reflected areas of tumour
necrosis. EnF has also been shown to change rapidly in
response to drug-induced variations in tumour interstitial
pressure [3] where nonenhancement represents failure of
perfusion of viable vessels. The EnF has not been
examined in cerebral tumours, where enhancement char-
acteristics are affected by a number of unique physiological
mechanisms: specifically the presence of the blood–brain
barrier and disease-related variations in intracranial pres-
sure. Although we have used the relationship between
tumour grade and EnF to begin to characterize this
biomarker it is important to state that we are attempting
to validate EnF as a biomarker and are not proposing it as a
method for clinical tumour grading at this stage.
Interestingly, we found that EnFIAUC60>0 provided no
discrimination between low and high grade tumours since
small degrees of contrast enhancement were detectable in
large portions of low grade tumours despite subjective lack
of enhancement. This is counterintuitive since low grade
tumours are commonly described as “nonenhancing” based
on subjective criteria. However, low grade tumours are
perfused and therefore contain small amounts of contrast
within the vascular space even where the blood–brain
barrier is intact, although IAUC60 values are expected to
be low. In high grade tumours higher values of IAUC60 are
expected since vascular fractions are far higher and
breakdown of the blood brain–barrier leads to extravasa-
tion of contrast medium. This is supported by the results of
this study where median values of IAUC60 were
significantly higher in grade IV (mean=4.43+
2.23 mMol s) than grade II (mean=1.23+0.79 mMol s)
tumours.
The relationship between EnF and IAUC will reflect a
combination of processes. In enhancing portions of a
tumour the amount of contrast observed within a voxel will
depend on blood flow, vascular fraction, endothelial
permeability and the size of the extravascular extracellular
space. These relationships are well understood and can be
described by a series of widely employed pharmacokinetic
Fig. 4 ROC curves for ∂EnF
and Pronin’s measure of en-
hancement as predictors of tu-
mour grade: a grade II versus
grade III gliomas, b grade II
versus grade IV gliomas, c grade
III versus grade IV gliomas and
d high (grades III and IV) versus
low (grade II) glioma
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models [20]. Pixels will be classified as nonenhancing
when the voxel contains too little contrast media to provide
a degree of enhancement sufficient to exceed the threshold
set for tissue classification. This may occur in necrotic
tumour or in perfused tumour where the blood–brain
barrier is intact or where flow is absent or considerably
reduced.
The observations presented here demonstrate a clear and
significant difference in the relationship between EnF and
IAUC in low and high grade tumours. Increasing the
threshold of IAUC60 above which a voxel is considered to
enhance caused the calculated enhancing fraction to fall, as
the proportion of “enhancing” voxels declines. In low
grade tumours increasing the IAUC60 threshold caused a
steep drop-off in EnF. In the grade IV tumours many voxels
contain a high concentration of contrast agent so that
increasing the IAUC60 threshold results in a more gradual
decline in EnF. These observations also indicate that the
use of a single definition of enhancement such as those
used in previous studies of systemic tumours [3, 5] may be
misleading and obscure information of potential biological
importance. We have therefore described two novel metrics
that characterize the relationship between EnF and IAUC:
∂EnF and EnFIAUC>2.5. ∂EnF demonstrated excellent dis-
crimination, with high sensitivity (93.7%) and specificity
(95.8%), between grade II and grade IV tumours, and
between grade III and IV tumours (sensitivity 95.83%,
specificity 100%; Fig. 4). ∂EnF also demonstrated the
highest AUC values of all variables on ROC analysis (these
differed significantly from EnFIAUC60>0 and Tofts’ %E on
comparison of grade II versus IV and EnFIAUC60>0 alone
for low versus high grade tumours). Both signal-intensity
based measures of enhancement also demonstrated sig-
nificant differences between grade II and IV tumours,
although considerable overlap was seen between high and
low grade tumours (Fig. 2). In addition, Pronin’s measure
of enhancement discriminated between grade III and IV
tumours; however, this did not differ significantly from
∂EnF on ROC analysis.
Identification of grade III tumours by imaging remains a
significant problem. Clinically they are treated as malig-
nant dedifferentiated tumours although their prognosis is
Table 1 Pairwise comparison of ROC curves
Grade II versus III Grade II versus IV Grade III versus IV Low versus high grade
Area under curve (AUC)
EnFIAUC60>0 0.563 0.549 0.417 0.552
EnFIAUC60>2.5 0.463 0.924 0.967 0.845
IAUC60 0.413 0.94 0.95 0.849
Pronin’s 0.538 0.94 0.967 0.871
∂EnF 0.438 0.982 0.992 0.888
Tofts’ 0.45 0.841 0.85 0.774
Pairwise comparisons of AUC (p values)
EnFIAUC60>0 versus EnFIAUC60>2.5 0.823 <0.001* 0.002* <0.001*
IAUC60 0.824 <0.001* 0.002* <0.001*
Pronin’s 0.85 <0.001* 0.004* 0.001*
∂EnF 1 <0.001* 0.003* <0.001*
Tofts’ 0.898 <0.001* 0.016* 0.006*
EnFIAUC60>2.5 versus IAUC60 0.251 0.442 0.28 0.853
Pronin’s 1 0.759 1 0.682
∂EnF 0.863 0.149 0.329 0.424
Tofts’ 0.92 0.14 0.072 0.249
IAUC60 versus Pronin’s 0.756 1 0.645 0.734
∂EnF 0.867 0.242 0.202 0.472
Tofts’ 0.787 0.095 0.113 0.262
Pronin’s versus ∂EnF 0.872 0.308 0.396 0.778
Tofts’ 0.932 0.066 0.062 0.104
∂EnF versus Tofts’ 0.936 0.024* 0.052 0.121
∂EnF has the largest AUC for differentiating grade II from IV, grade III from IV and low from high grade tumours
AUC area under curve
*Significance taken as p<0.05
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better than glioblastoma. Any classification system would
therefore ideally identify them as a separate subgroup but
should at least not group them together with grade 2
tumours. Unfortunately many studies have been unable to
separate grade II and grade III tumours on the basis of
imaging biomarkers. White et al. studied 24 oligoden-
drogliomas (16 grade II and 8 grade III) by using a signal-
intensity-based measure of enhancement and found no
difference between grade II and grade III tumours [14]. The
current study also failed to differentiate between these two
groups. Other studies have been able to differentiate grade
III from grade II but not from grade IV [9]. The
development of imaging biomarkers to accurately identify
grade III tumours is hampered by considerable variability
in the accuracy of pathological classification and by the
frequent occurrence of grade II tumours with an oligoden-
droglial component which are known to be relatively
vascular [21]. This was the case in the current study as 62%
of low grade tumours had significant oligodendroglioma
components. In addition we had only five grade III tumours
so that we can draw no conclusions concerning the accurate
grading of this group.
One potential weakness of the current study is the use of
an IAUC threshold derived from a small subgroup of the
study population. However, we are not proposing this
threshold for clinical use but only to support binning of the
datasets in this study for statistical comparison. The study
is also limited by the relatively small numbers (only 5
grade III gliomas) and by failure to separate tumours into
histological subtypes.
In conclusion, metrics based on the enhancing tumour
fraction show significant differences between low and high
grade glioma. Their use as a tool for clinical grading is
limited by failure to differentiate grade II and grade III
tumours. However, as we stated above, the aim of this
study was to provide an initial description of the behaviour
of enhancing-fraction-based metrics in intracerebral tu-
mours and not to produce a clinical grading tool. The ∂EnF
metric incorporates components of both EnF and quanti-
tative enhancement behaviour. This relationship is likely to
be affected by factors that will not be reflected in more
conventional enhancement metrics, particularly tumour
interstitial and intracranial pressure. Although further work
is clearly required to further characterise and validate these
metrics as potential biomarkers the characteristics demon-
strated here make them of potential interest for the
monitoring of low grade glioma for the detection of
malignant transformation and for detection of changes in
hydrodynamic equilibrium that occur with tumour growth
and in response to novel antivascular treatments in high
grade glioma.
Conclusion
We have described two new biomarkers (∂EnF and
EnFIAUC>2.5) which characterize the relationship between
the intensity of tumour enhancement and enhancing
fraction. These markers are simple to derive and provide
excellent discrimination between grade II and IV cerebral
Fig. 5 Scatter plots of EnFIAUC60>0in relation to tumour histological
subtype for grade II and III gliomas. A astrocytoma, OA
oligoastrocytoma, O oligodendroglioma, AA anaplastic astrocytoma,
AO anaplastic oligodendroglioma. There was a tendency for
EnFIAUC60>2.5to increase in the presence of oligodendroglial com-
ponent in both grade II and grade III tumours, with higher
EnFIAUC60>0 in oligoastrocytomas (squares, n=3) and oligoden-
drogliomas (triangles, n=7) than in astrocytomas (diamonds, n=6)
and higher in the anaplastic astrocytomas (crosses, n=4) than the
anaplastic oligodendroglioma (scored-through cross, n=1). In
addition, there was a suggestion that the anaplastic astrocytomas
had a higher EnFIAUC60>0 than the astrocytomas and the
anaplastic oligodendroglioma had a higher EnFIAUC60>0than the
oligodendrogliomas
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gliomas. We believe that these findings justify further
research to evaluate these potential biomarkers and assess
their role in monitoring treatment response and predicting
outcome and early malignant transformation.
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Appendix
Both Pronin’s and Tofts measures of enhancement were
calculated using modified techniques based on the original
literature [5, 6, 8]. Analysis was performed in MATLAB
(The MathWorks Inc., Natick, Massachusetts) using the
pre- and post-contrast T1-weighted images through the
lesion. As a result of the sagittal oblique acquisition of
the images, contralateral normal-appearing white matter
(NAWM) could not be assessed and the analysis was,
therefore, based upon remote NAWM. An area of remote
NAWM was identified distinct and separate from the
tumour and a VOI was defined. The same tumour VOI used
in the perfusion analysis was used in the calculation of
signal-intensity-based enhancement.
Pronin’s measure of the degree of enhancement [5, 6]:




StumourVOI+C = mean post-contrast signal intensity for
whole tumour volume of interest
SNAWMVOI+C = mean post-contrast signal intensity for
whole remote NAWMvolume of interest
This produced a measure of enhancement for the whole
tumour VOI.
Tofts’ measure of enhancement (%E) [8]:




Stumour+C = signal intensity for tumour voxel post-contrast
Stumour = signal intensity for tumour voxel pre-contrast
SNAWM = mean signal intensity for remote NAWM on
both pre- and post-contrast imaging
This produced a measure of enhancement for each voxel
within the tumour VOI. To allow comparison with other
measures of enhancement median values were calculated.
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